Skip to main content
. 2022 Sep 14;54(5):971–980. [Article in Chinese] doi: 10.19723/j.issn.1671-167X.2022.05.026

表 4.

不同生物标志物表达组间患者疗效汇总

Efficacy summary by biomarker status

Items PD-L1+ (n=55) PD-L1- (n=62) MSI-H (n=9)
Atezolizumab (n=42) Atezolizumab + gemcitabine + cisplatin (n=13) Atezolizumab (n=56) Atezolizumab + gemcitabine + cisplatin (n=6) Atezolizumab (n=9)
Abbreviations and explain as in Figure 1, Table 1 and 3. a, DCR is calculated by taking the sum of CR, PR, and SD.
ORR (95%CI)/% 11.9 (3.98-25.63) 46.2 (19.22-74.87) 8.9 (2.96-19.62) 33.3 (4.33-77.72) 11.1 (0.28-48.25)
  CR, n(%) 0 0 0 0 0
  PR, n(%) 5 (11.9) 6 (46.2) 5 (8.9) 2 (33.3) 1 (11.1)
  SD, n(%) 16 (38.1) 5 (38.5) 25 (44.6) 4 (66.7) 4 (44.4)
  DCRa, n(%) 21 (50.0) 11 (84.6) 30 (53.6) 6 (100.0) 5 (55.6)
  PD, n(%) 17 (40.5) 1 (7.7) 21 (37.5) 0 4 (44.4)
  NE, n(%) 0 0 0 0 0
  Missing, n(%) 4 (9.5) 1 (7.7) 5 (8.9) 0 0
Median DOR (95%CI)/months 20.8 (6.9-20.8) NE (5.6-NE) 17.1 (8.0-NE) NE (NE) NE
Median PFS (95%CI)/months 2.8 (1.4-4.4) 6.9 (5.5-NE) 2.7 (1.4-3.8) 5.8 (3.3-NE) 4.2 (1.4-15.0)
Median OS (95%CI)/months 14.9 (6.1-29.9) NE (9.6-NE) 9.7 (6.6-13.2) NE (3.8-NE) 15.0 (9.7-NE)
6-month OS rate (95%CI)/% 67 (52-82) 100 (100-100) 64 (52-77) 67 (29-100) 78 (51-100)
1-year OS rate (95%CI)/% 50 (34-67) 75 (33-100) 39 (26-52) NE (NE) 65 (32-97)
Duration of follow-up/months, M (Range) NA NA NA NA NA